Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai AB Pharmatech Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a focused examination path.
TRAN, ERIC is the busiest examiner, with 1 pending matter. Counsel can concentrate on the assigned application and tailor the response to the issues in that examination record.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, ERIC | 1 | 69.8% | +19.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18786042 | MULTI-TARGETED TYROSINE KINASE INHIBITORS EFFECTIVE IN ANTITUMOR USES | TRAN, ERIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18786042 | MULTI-TARGETED TYROSINE KINASE INHIBITORS EFFECTIVE IN ANTITUMOR USES | TRAN, ERIC | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18786042 | MULTI-TARGETED TYROSINE KINASE INHIBITORS EFFECTIVE IN ANTITUMOR USES | TRAN, ERIC | 1629 | §103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai AB Pharmatech Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Eric Tran has the most, with 1 of Shanghai AB Pharmatech Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
